Enterprise Value

819.1M

Cash

252.7M

Avg Qtr Burn

-28.18M

Short % of Float

12.76%

Insider Ownership

0.31%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Barzolvolimab (CDX-0159) Details
Eosinophilic Esophagitis, Eosinophilic Gastritis

Phase 2

Data readout

Phase 2

Update

Barzolvolimab (CDX-0159) (KIT receptor) Details
Skin disease/disorder, Prurigo nodularis

Phase 2

Initiation

CDX-585 Details
Solid tumor/s, Cancer

Phase 1

Data readout

CDX-1140 (CD40 agonist) Details
Solid tumor/s, Cancer, Diffuse large B cell lymphoma

Failed

Discontinued

Failed

Discontinued